And how far can we go with AI before we cross the boundaries set by ethics and regulation?
It is time we dared to tackle the difficult issues in this debate.
Technology opportunities and challenges
AI and machine learning have already shown their capacity to revolutionize drug development. For example, AI-powered platforms have enabled the analysis of huge amounts of molecular data, making it possible to find new drug candidates in a fraction of the time it traditionally took. One project managed to reduce the time needed for drug discovery from years to months, resulting in significant savings.
This development also opens the door to personalized medicine, where AI models can analyse genetic information and create tailored treatment plans for each patient.
Getting a cancer treatment designed for your unique genetic profile is no longer science fiction - it is already being tested in several places.
But where do you draw the line?
Despite these opportunities, it is impossible to ignore the challenges and risks posed by AI's entry into the industry.
One of the biggest questions is whether AI can, or should, take over decisions previously made by scientists and doctors?
In countries such as the US and China, governments have already started using AI to automate parts of clinical trials and drug evaluations. But is this really the way forward?
The EU's AI Act (2023 ) is an example of legislation that seeks to balance these opportunities with a clear framework. It requires AI systems that handle sensitive health data or are used for clinical decisions to meet strict transparency and security requirements. This protects patients' rights, but has also been criticized for slowing down innovation in Europe.
At the same time, it requires pharmaceutical companies to rethink how they use AI - and this is where things get really interesting.
Ethical dilemmas in a digital world
The rise of AI in drug development also raises ethical questions. If AI takes a greater Location in the research process, do we risk losing insights that can only be reached through human intuition and experience?
And who is responsible if an AI-driven analysis turns out to be wrong and leads to a bad decision in a clinical trial?
These issues are no longer hypothetical, but need to be taken seriously by businesses, researchers and policy makers.
At the same time, AI can contribute to greater equity in healthcare. By analyzing data from different patient groups, AI can identify and counteract unconscious biases in treatment methods, for example, ensuring that Pharma is equally effective for everyone, regardless of background or gender. But this requires clear guidelines and controls to avoid AI itself creating new biases.
A future with AI - together, not instead of
AI will not replace scientists and doctors, but it has the potential to become an invaluable partner in their work. The challenge is to create an environment where AI can be fully used without losing sight of the ethical values that must always be at the center.
We need a debate that dares to question and set clear rules to protect patients' rights, but is not afraid to embrace the new.
Because that is how we can drive development forward. Let's dare to test the limits and find the balance between innovation and safety. Only then can we ensure that AI becomes a catalyst for better, faster and fairer drug development - where both researchers and AI contribute with their unique strengths.
AI is no longer something diffuse in the periphery, somewhere in a distant tomorrow, but rather, AI is already our everyday life and therefore it is fervently important to participate in the debate and in the discussions already today.
You are coming, right?
